Brief: Hansa Biopharma Sees Q1 Revenue Of SEK 54 Mln
02/04/2024 06:04
April 2 (Reuters) - Hansa Biopharma AB HNSA.ST :
* EXPECTS STRONG FIRST QUARTER 2024 SALES PERFORMANCE
* EXPECTS REVENUE OF SEK 54M INCLUDING PRODUCT SALES OF SEK 48M - AN INCREASE OF 10% VERSUS
PRIOR
QUARTER AND A 234% INCREASE VERSUS Q1 2023
Source text for Eikon: ID:nWkrb7Gyrd
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS